196 related articles for article (PubMed ID: 7542289)
1. QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens.
Horny HP; Wehrmann M; Schlicker HU; Eichstaedt A; Clemens MR; Kaiserling E
J Clin Pathol; 1995 Apr; 48(4):291-4. PubMed ID: 7542289
[TBL] [Abstract][Full Text] [Related]
2. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.
Soligo D; Delia D; Oriani A; Cattoretti G; Orazi A; Bertolli V; Quirici N; Deliliers GL
Leukemia; 1991 Dec; 5(12):1026-30. PubMed ID: 1723130
[TBL] [Abstract][Full Text] [Related]
3. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes.
Baur AS; Meugé-Moraw C; Schmidt PM; Parlier V; Jotterand M; Delacrétaz F
Eur J Haematol; 2000 Feb; 64(2):71-9. PubMed ID: 10997326
[TBL] [Abstract][Full Text] [Related]
4. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
5. Immunotyping of blasts in refractory anaemia with excess of blasts.
Oertel J; Kleiner S; Huhn D
Br J Haematol; 1993 Jun; 84(2):305-9. PubMed ID: 7691147
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens.
Toth B; Wehrmann M; Kaiserling E; Horny HP
J Clin Pathol; 1999 Sep; 52(9):688-92. PubMed ID: 10655992
[TBL] [Abstract][Full Text] [Related]
7. CD34/QBEND10 immunostaining in the bone marrow trephine biopsy: a study of CD34-positive mononuclear cells and megakaryocytes.
Torlakovic G; Langholm R; Torlakovic E
Arch Pathol Lab Med; 2002 Jul; 126(7):823-8. PubMed ID: 12088452
[TBL] [Abstract][Full Text] [Related]
8. CD34 immunophenotyping of blasts in myelodysplasia.
Oertel J; Huhn D
Leuk Lymphoma; 1994 Sep; 15(1-2):65-9. PubMed ID: 7532058
[TBL] [Abstract][Full Text] [Related]
9. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
[TBL] [Abstract][Full Text] [Related]
10. CD34 immunohistochemical staining of bone marrow biopsies in myelodysplastic syndromes.
Min YH; Lee ST; Min DW; Kim TS; Lee CH; Lee BK; Hahn JS; Ko YW
Yonsei Med J; 1995 Mar; 36(1):1-8. PubMed ID: 7537931
[TBL] [Abstract][Full Text] [Related]
11. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
13. CD34 immunostaining of bone marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukemia.
Orazi A; Neiman RS; Cualing H; Heerema NA; John K
Am J Clin Pathol; 1994 Apr; 101(4):426-8. PubMed ID: 7512785
[TBL] [Abstract][Full Text] [Related]
14. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes.
Soligo DA; Oriani A; Annaloro C; Cortelezzi A; Calori R; Pozzoli E; Nosella D; Orazi A; Deliliers GL
Am J Hematol; 1994 May; 46(1):9-17. PubMed ID: 7514357
[TBL] [Abstract][Full Text] [Related]
15. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia.
Span LF; Dar SE; Shetty V; Mundle SD; Broady-Robinson L; Alvi S; Raymakers RA; de Witte T; Raza A
Leukemia; 1998 Nov; 12(11):1685-95. PubMed ID: 9823942
[TBL] [Abstract][Full Text] [Related]
16. Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry.
Fuchigami K; Mori H; Matsuo T; Iwanaga M; Nagai K; Kuriyama K; Tomonaga M
Leuk Res; 2000 Feb; 24(2):163-74. PubMed ID: 10654453
[TBL] [Abstract][Full Text] [Related]
17. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
18. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.
Kanter-Lewensohn L; Hellström-Lindberg E; Kock Y; Elmhorn-Rosenborg A; Ost A
Eur J Haematol; 1996 Mar; 56(3):124-9. PubMed ID: 8598230
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
20. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens.
Orazi A; Albitar M; Heerema NA; Haskins S; Neiman RS
Am J Clin Pathol; 1997 Mar; 107(3):268-74. PubMed ID: 9052376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
